Whereas a rare disease or disorder is a disease or disorder that affects a small number of patients; Whereas, in the United States, a rare disease or disorder affects fewer than 200,000 individuals; Whereas, as of the date of the adoption of this resolution, more than 25,000,000 individuals in the United States are living with at least 1 of the more than 7,000 known rare diseases or disorders; Whereas children with rare diseases or disorders account for a significant portion of the population affected by rare diseases or disorders in the United States; Whereas many rare diseases and disorders are serious and life-threatening; Whereas this year marks the 40th anniversary of the enactment of the Orphan Drug Act ( Public Law 97–414 ; 96 Stat. 2049), a landmark law enabling tremendous advances in the research and treatment of rare diseases and disorders; Whereas, in 2022, the Center for Drug Evaluation and Research, in the Food and Drug Administration (referred to in this preamble as FDA ), established the Accelerating Rare disease Cures Program with a vision of speeding and increasing the development of effective and safe treatment options to address the unmet needs of patients with rare diseases; Whereas the 117th Congress passed into law as part of the Consolidated Appropriations Act, 2023 ( Public Law 117–328 ; 136 Stat. 4459), provisions creating the rare disease endpoint advancement pilot program in the FDA to support the development of novel efficacy endpoints to help facilitate the development and timely approval of rare disease treatments; Whereas, although the FDA has approved more than 1,100 orphan indications for drugs and biological products for the treatment of rare diseases and disorders, more than 90 percent of rare diseases do not have a treatment approved by the FDA for their condition; Whereas limited treatment options and financing life-altering and lifesaving treatments can be challenging for individuals with rare diseases or disorders and their families